Diapin Therapeutics Competitors and Similar CompaniesClear all
Diapin Therapeutics's competitors and similar companies include Larimar Therapeutics, Oramed Pharmaceuticals, Kowa Pharmaceuticals America and MannKind Corporation.
 Diapin Therapeutics Diapin Therapeutics is a biotech company focused on the treatment of Type 2 diabetes. |  Larimar Therapeutics Larimar Therapeutics (formerly known as Zafgen) is a biopharmaceutical company dedicated to improving the health and well-being of patients affected by obesity and complex metabolic disorders. |  Oramed Pharmaceuticals Oramed Pharmaceuticals is the developer of an innovative technology to transform injectable treatments into oral therapies. |  Kowa Pharmaceuticals America Kowa Pharmaceuticals America is a pharmaceutical company focused on cardiometabolic diseases. |  MannKind Corporation MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients. | |
Founding Date | Founding Date 2011 | Founding Date 2005 | Founding Date 2006 | Founding Date 2008 | Founding Date 1991 |
Type | Type Private | Type Public | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Ann Arbor, US HQ | Locations Bala Cynwyd, US HQ | Locations New York, US HQ Jerusalem, IL | Locations Montgomery, US HQ | Locations Westlake Village, US HQ Danbury, US |
Employees | Employees 5 | Employees 782% decrease | Employees 1417% increase | Employees 3521% increase | Employees 39513% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 496.4 m | Valuation ($) 94.2 m | Valuation ($) N/A | Valuation ($) 1.9 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $2m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $349m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $2m (FY, 2025) | Cost of goods N/A | Cost of goods $26.8m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $13k (FY, 2025) | Gross profit N/A | Gross profit $322.2m (FY, 2025) |
Net income | Net income N/A | Net income ($165.7m) (FY, 2025) | Net income $64m (FY, 2025) | Net income N/A | Net income $5.9m (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 132.2m | Total funding raised $ 1m | Total funding raised N/A | Total funding raised $ 200m |
For sources of this data, please see the company profile
View Company Profiles
Larimar Therapeutics
HQ
Bala Cynwyd, US
Employees
7
Larimar Therapeutics (formerly known as Zafgen) is a biopharmaceutical company dedicated to improving the health and well-being of patients affected by obesity and complex metabolic disorders.
View companyOramed Pharmaceuticals
HQ
New York, US
Employees
14↑ 17% increase
Oramed Pharmaceuticals is the developer of an innovative technology to transform injectable treatments into oral therapies.
View companyKowa Pharmaceuticals America
HQ
Montgomery, US
Kowa Pharmaceuticals America is a pharmaceutical company focused on cardiometabolic diseases.
View companyMannKind Corporation
HQ
Westlake Village, US
Employees
395↑ 13% increase
MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.
View company